Participated · Seed · Jun 2026

Qubic develops Kinetic Inductance Traveling Wave Parametric Amplifiers (KI-TWPAs), ultra-low-noise, wide-bandwidth microwave amplifiers intended for reading out superconducting qubits and compatible with other qubit modalities. Its amplifiers derive nonlinear inductance from the transmission line material rather than Josephson junctions, aiming for a more robust, scalable device that operates near the quantum limit and supports multiplexed qubit readout. Qubic reports heat dissipation for its amplifiers is expected to be cut to under 0.1 mW per amplifier, addressing a key bottleneck in cryogenic quantum systems. The company has sold its devices to Quantum Machines and plans to scale manufacturing to meet demand from quantum computing and defense customers. Qubic is also developing an RF quantum sensing platform leveraging its amplifier technology for applications such as threat detection and covert communications, and intends to grow its team three-fold to achieve these goals.

Participated · Equity · Apr 2026

Opalia cultivates mammary cells in bioreactors to produce complete milk—including proteins, fats, and sugars—intended as a drop-in replacement for conventional fluid or powdered milk. The company positions its approach as distinct from precision fermentation by producing whole milk rather than single milk proteins. Opalia targets the global dairy market through a B2B licensing and supply model rather than direct-to-consumer sales. It has signed paid commercial pilot agreements with established dairy players, including Hoogwegt and the Canadian division of a major dairy group, with partnerships across five countries on three continents. Opalia plans to scale a modular bioreactor system using proceeds from the CAD 3.2M seed round and aims for a commercial launch in 2028 while pursuing regulatory approvals in North America, Europe, and Asia.

Participated · Equity · Mar 2025

RetinaLogik is a Calgary-based startup that has developed a VR-AI-powered platform and portable headset for eye care. The system enables essential tests, including visual field exams, while streamlining the testing process to improve patient comfort and clinic efficiency. The device is ISO-13485 and MDSAP certified and is FDA registered; it has received Health Canada Class II medical device approval. RetinaLogik says the system can reduce upfront equipment costs by up to 90% compared with traditional equipment and includes multilingual support to bridge clinic communication gaps. The company completed a $1.1M funding round and received support from investors and community partners. RetinaLogik plans to expand adoption across North America and beyond to close critical gaps in eye care, enable earlier detection and treatment, and prevent irreversible vision loss. RetinaLogik’s core product is a portable eye-test platform that uses a virtual reality headset and AI-driven analytics to collect and analyze visual field data. While wearing the headset, patients are guided through a tutorial in their own language and perform vision tests whose results can be reviewed remotely by specialists. The device is already deployed in clinics across Canada and has been used in partnerships to deliver testing in senior homes. Co‑founders Abdullah Sarhan and Julia St.Amand began work on the project in 2018 and built the first prototype in 2019 after years of iteration and clinic testing. With new funding, the company plans to scale its team, add new vision tests, support device sales, and pursue Class 2 certification from Health Canada. To date RetinaLogik has raised CA$1.7M in total funding, including the recent CA$783,000 pre‑seed round.

Participated · Seed · Sep 2024

Ayrton Energy develops a non-toxic liquid organic hydrogen carrier (LOHC) that stores hydrogen at room temperature and pressure. The company’s LOHC is said to look like water and stores hydrogen through a hydrogenation/dehydrogenation process similar to how vegetable oils are hydrogenated to make margarine. Ayrton uses commercially available, electrolyzer-like equipment and a modular approach so scaling requires more modules rather than larger parts. Its LOHC can be transported using existing infrastructure—pipelines, rail cars, and tanker trucks—and the firm says it carries about twice as much hydrogen per liter as compressed hydrogen. The company reports round-trip energy use lower than liquefied hydrogen, ammonia, or methanol and slightly higher than compressed hydrogen, and highlights lower up-front costs from reusing current fuel infrastructure. Co‑founders Natasha Kostenuk (CEO) and Brandy Kinkead plan to use recent funding to scale the technology toward producing two to three tons of hydrogen per day by 2027.

Participated · Series A · Jul 2024

PulseMedica is developing an ophthalmic medical-device platform that uses 3D computer vision, real-time tracking, and femtosecond laser technology for non-invasive, automated imaging and treatment of eye floaters and other vitreoretinal disease. The company is advancing a floater imaging device and is conducting laser safety and feasibility studies to enable a first-in-human clinical trial. Recent funding is being used to accelerate clinical validation, support ongoing studies, and expand the technical and business teams in preparation for commercialization and regulatory approvals. Since 2020 PulseMedica has raised over CA$16M, including a CA$6.5M investment from a multinational strategic in 2023; it announced CA$12M raised to date as part of its pre-Series A financing. Product development progress includes seven prototype devices and the filing of 14 patents. PulseMedica is attracting interest from potential lead investors for an upcoming Series A round. PulseMedica is a University of Alberta spinoff building a fully automated platform that images the eye, determines treatment locations, and delivers therapy using lasers instead of injections. The company aims to demonstrate the safety and accuracy of its imaging and laser delivery systems through a first clinical trial beginning in June. That trial will test the system on 10–15 Edmonton patients with diabetic retinopathy. PulseMedica is finishing device build and pursuing Health Canada approvals ahead of the study, and has recently expanded its team and established a medical advisory board of ophthalmologists. The startup is working out of the MNP Tower in downtown Edmonton and plans to move to a larger space this summer. Financially, PulseMedica raised an oversubscribed $2.6M seed round and previously raised $1M in a 2020 pre-seed plus roughly $1M in grants. Once it accumulates clinical data the company expects to pursue a Series A targeting about US$10M, with a goal of making the technology available to clinicians by 2024.